戻る Agenda
Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact
Session Chair(s)
Martine Dehlinger-Kremer, PhD
Sn Drug Development Strategy Lead Pediatrics, UCB Biosciences, Germany
Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact
Speaker(s)
Ralph Bax, MD, PhD
Head of the Paediatric Medicines Office, European Medicines Agency, Netherlands
EMA Regulatory Science Strategy 2025 - How Will It Impact Paediatric Development?
Dimitrios Athanasiou, MBA
Patient Advocate , WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS, Greece
Panel Discussion
Geneviève Le Visage, PharmD, MSc
Head EU RA Policy and Liaison, Novartis Pharma AG, Switzerland
Panel Discussion
Siri Wang
Scientific Director; PDCO delegate, Norwegian Medical Products Agency, Norway
Panel Discussion